Jan 9, 2015: Started in-home hospice support (building team, weekly visits, etc.)
Nov 11, 2014: Decided to not pursue further systemic cancer treatment.
Oct 28, 2014: Discontinued trial. Disease progression.
Oct 7, 2014: Cycle #3 of pembro.
Sept 16, 2014: Cycle #2 of pembrolizumab.
Sept 4, 2014: The study drug in my clinical trial, pembrolizumab, is approved by FDA for use in melanoma, proprietary name Keytruda (New York Times). This is an initial, limited approval. Original Merck press release.
August 26, 2014: Begin participation in a Phase 1b clinical trial of pembrolizumab, 200 mg once every 3 weeks. I am in cohort B2.
June-July 2014: Two rounds of TPF chemotherapy (docetaxel, cisplatin, 5-fluorouracil); no appreciable shrinkage of tumors. Discontinued. Last one 6/30.
May 2014: Recurrence and metastasis of same confirmed.
June-Sept 2013: Surgery and 7 weeks of daily radiation, to reduce recurrence.
May 2013: Squamous cell carcinoma of the R nasal cavity diagnosed after routine polypectomy.